Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus

Fig. 2

HM71224 inhibits B cells and autoantibody. Quantitative analysis of splenic B cell populations was performed by flow cytometry. HM71224 dose-dependently reduced activated B cells (a), germinal center B cells (b) and showed a significant ameliorative effect on activated B cells at 30 mg/kg after treatment for 20 weeks in MRL/lpr mice (n = 11 per vehicle-treated group, n = 12 per HM71224-treated group). Treatment with HM71224 for 24 weeks in NZB/W F1 mice resulted in a significant decrease in both activated (c) and plasma B cells (d) (n = 8 per vehicle-treated group, n = 9 per 3 mg/kg of HM71224-treated group, n = 12 per 10 and 30 mg/kg of HM71224-treated group). Serum anti-dsDNA IgG was measured by ELISA at the end of the study. HM71224 dose-dependently inhibited autoantibody in both mouse models (e, f). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle control, analyzed by the Kruskal–Wallis test

Back to article page